{
    "clinical_study": {
        "@rank": "21822", 
        "arm_group": [
            {
                "arm_group_label": "cell Therapy 1", 
                "arm_group_type": "Active Comparator", 
                "description": "intramyocardial administration of autologous bone marrow mononuclear cells during the operation coronary artery bypass grafting"
            }, 
            {
                "arm_group_label": "non cell therapy", 
                "arm_group_type": "Placebo Comparator", 
                "description": "intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml"
            }, 
            {
                "arm_group_label": "cell therapy 2", 
                "arm_group_type": "Active Comparator", 
                "description": "intramyocardial and intracoronary administration of autologous bone marrow mononuclear cells during coronary artery bypass grafting"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study evaluate the effect of the method of administration of autologous\n      bone marrow mononuclear cells for the duration of of functioning aorto-coronary bypass\n      grafts in the surgical treatment of coronary heart disease, to assess the degree of\n      effectiveness depending on the method of transplantation (intramyocardial, Intracoronary)."
        }, 
        "brief_title": "Autologous Bone Marrow Mononuclear Cells in the Combined Treatment of Coronary Heart Disease", 
        "completion_date": {
            "#text": "February 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Ischemic Heart Disease", 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease", 
                "Heart Diseases", 
                "Ischemia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men and women from 18 to 80 years\n\n          -  Patients with angina pectoris III-IV functional class\n\n          -  Patients signed informed consent\n\n        Exclusion Criteria:\n\n          -  Intolerance of heparin and HES (hydroxyethyl starch)\n\n          -  Hypothyroidism and hyperthyroidism.\n\n          -  Associated pathology with a projected lifespan limitation to 3 years.\n\n          -  infection  diseases\n\n          -  Simultaneous participation in another study.\n\n          -  Pregnancy.\n\n          -  Severe mental disorder.\n\n          -  Refusal of a patient to participate in the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 1, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02059512", 
            "org_study_id": "NBK-2901-AMNKM"
        }, 
        "intervention": {
            "arm_group_label": [
                "cell Therapy 1", 
                "cell therapy 2"
            ], 
            "intervention_name": "coronary artery bypass grafting with administration of autologous bone marrow stem cells", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "ischemic heart disease", 
            "autologous bone marrow mononuclear cells", 
            "coronary artery bypass grafting"
        ], 
        "lastchanged_date": "February 10, 2014", 
        "location": {
            "contact": {
                "email": "nemk_as@mail.ru", 
                "last_name": "Alexander S Nemkov, MD, Ph.D", 
                "phone": "8 921 795 00 47"
            }, 
            "contact_backup": {
                "email": "vladimir_komok@mail.ru", 
                "last_name": "Vladimir V Komok", 
                "phone": "8 904 632 19 00"
            }, 
            "facility": {
                "address": {
                    "city": "St. Petersburg", 
                    "country": "Russian Federation", 
                    "zip": "197089"
                }, 
                "name": "First Pavlov State Medical University of St. Petersburg"
            }, 
            "investigator": [
                {
                    "last_name": "Vladimir V Komok, Doctor", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Sergey \u0410 Beliy, Doctor", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Russian Federation"
        }, 
        "number_of_arms": "3", 
        "official_title": "Influence of the Administration of Autologous Bone Marrow Mononuclear Cells for the Duration of Functioning Aorto-coronary Bypass Grafts in the Surgical Treatment of Coronary Heart Disease", 
        "other_outcome": {
            "measure": "Percentage of functioning grafts in patients with implantation of autologous bone marrow mononuclear cells.", 
            "safety_issue": "No", 
            "time_frame": "up to 60 months"
        }, 
        "overall_contact": {
            "email": "nemk_as@mail.ru", 
            "last_name": "Alexander S Nemkov, MD, Ph.D", 
            "phone": "8 921 795 00 47"
        }, 
        "overall_contact_backup": {
            "email": "vladimir_komok@mail.ru", 
            "last_name": "Vladimir V Komok", 
            "phone": "8 904 632 19 00"
        }, 
        "overall_official": {
            "affiliation": "First Pavlov State Medical University of St. Petersburg.", 
            "last_name": "Alexander S Nemkov, MD, Ph.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Russia: Ministry of Health of the Russian Federation"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "All-cause mortality associated with the progression of basic disease", 
            "safety_issue": "No", 
            "time_frame": "up to 60 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02059512"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Quality of life", 
            "safety_issue": "No", 
            "time_frame": "one year"
        }, 
        "source": "St. Petersburg State Pavlov Medical University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "St. Petersburg State Pavlov Medical University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}